Actively Recruiting
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
Led by Kerry O'Rourke · Updated on 2024-07-03
60
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
K
Kerry O'Rourke
Lead Sponsor
S
Shriners Hospitals for Children
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if a pain medication called liposomal bupivacaine (brand name EXPAREL®) with epinephrine will provide better pain control, increased activity, and reduced use of opioids compared with the standard treatment for patients age 6 years and older with cleft lip and palate who have had an alveolar bone graft surgery. Investigators will look at: * pain scores at hip and jaw sites * opioid use in amount and frequency * scores on activity questionnaires Researchers will compare the results of these items with those of patients who had the standard treatment of bupivacaine with epinephrine.
CONDITIONS
Official Title
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 6 years and older with cleft lip and/or palate
- Scheduled for alveolar bone graft surgery
You will not qualify if you...
- Patients under 6 years of age
- History of allergic or adverse reaction to EXPAREL, epinephrine, or bupivacaine
- History of cardiovascular disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shriners Children's Chicago
Chicago, Illinois, United States, 60707
Actively Recruiting
Research Team
C
Chad A. Purnell, MD
CONTACT
B
Benjamin M. Smith, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here